Quality of life improvements in patients with PsA who achieve remission or low disease activity targets: results from two clinical trials of ixekizumab at three years of treatment by Coates, LC, Birt, J, Kronbergs, A, Bolce, R, Bradley, AJ, Park, SY, Helliwell, PS

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-... by Coates, LC, Mease, P, Kronbergs, A, Helt, C, Sandoval, D, Park, SY, Combe, B, Nash, P, Deodhar, A

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-... by Coates, L, Mease, P, Kronbergs, A, Helt, C, Sandoval, D, Park, SY, Combe, B, Nash, P, Deodhar, A